PF-AtlasКлинические испытания › NCT01844778

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder Versus Nebulised Tobramycin Inhalation Solution and Nebulised Colistimethate

Tobramycin Inhalation Powder · Фаза 4

ID реестра
NCT01844778
Фаза
Фаза 4
Статус
Завершено
Препарат / вмешательство
Tobramycin Inhalation Powder
Спонсор
Novartis Pharmaceuticals
Начало
2013-08
Набор участников
60
Центры
21

Об исследовании

The purpose of this interventional Phase IV study was to explore the ease of use of TIP and prevalence of microbial contamination of the T-326 Inhaler compared with TIS and colistimethate administered via nebuliser for the treatment of Cystic Fibrosis (CF) patients chronically infected with P. aeruginosa. It was anticipated that the data from this study would provide clinicians with further guidance on the relative differences between the speed and ease of use of these treatments as well as useful information on the prevalence of microbial contamination of the inhalation devices in "real world" use.

Открыть NCT01844778 на ClinicalTrials.gov →

Связанные материалы

Связанные исследования

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT01844778 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.